FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation

PURPOSE: Lapatinib is a candidate drug for treatment of trastuzumab-resistant, human epidermal growth factor receptor 2 (HER2)–positive gastric cancer (GC). Unfortunately, lapatinib resistance renders this drug ineffective. The present study investigated the implication of forkhead box O1 (FOXO1) si...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jinju, Choi, Yiseul, Ko, Young San, Kim, Younghoon, Pyo, Jung-Soo, Jang, Bo Gun, Kim, Min A, Lee, Jae-Seon, Chang, Mee Soo, Park, Jong-Wan, Lee, Byung Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784629/
https://www.ncbi.nlm.nih.gov/pubmed/28343375
http://dx.doi.org/10.4143/crt.2016.580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784629/
https://www.ncbi.nlm.nih.gov/pubmed/28343375
http://dx.doi.org/10.4143/crt.2016.580

Ejemplares similares